首页> 外文期刊>International journal of gastrointestinal cancer >Bowel obstruction in patients with metastatic cancer: does intervention influence outcome?
【24h】

Bowel obstruction in patients with metastatic cancer: does intervention influence outcome?

机译:转移性癌症患者的肠梗阻:干预会影响预后吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Both surgical and nonsurgical options are available to treat bowel obstruction in patients with metastatic cancer. The goal is straightforward: to restore bowel patency and palliate the symptoms of obstruction. Yet the most appropriate management is often a challenging decision.Aim of the Study: We sought to review our experience in managing patients with metastatic cancer and bowel obstruction.Methods: A retrospective review was performed to identify all patients admitted at University of Wisconsin Hospital between 1993 and 2000 with the diagnoses of both bowel obstruction and metastatic cancer. Demographic data, type of management, postoperative complications, and outcome were analyzed.Results: A total of 114 patients with primarily colorectal or gynecologic malignancies were identified. Patients' first bowel obstructions were managed in one of two ways: (1) definitive surgical intervention (n = 47), or (2) conservative management (n = 67). The median overall survival was 3 mo for the entire study group. There was no significant difference in overall or obstruction-free survival based on management, presence of recurrent bowel obstruction, or type of primary cancer. The only factor that was significant in predicting poor overall survival included a disease-free interval of less than 1 yr (time of diagnosis of primary cancer to time of bowel obstruction, p = 0.002).Conclusions: Bowel obstruction in patients with metastatic cancer is a terminal event, with a 3-mo median survival. Because there is no difference in overall or obstruction-free survival based on management, the treatment for palliation of bowel obstruction in patients with metastatic cancer should be individualized.
机译:背景:外科手术和非外科手术均可用于治疗转移性癌症患者的肠梗阻。目标很简单:恢复肠通畅并缓解阻塞症状。然而,最合适的管理通常是一个具有挑战性的决定。研究目的:我们试图回顾我们在治疗转移性癌症和肠梗阻患者方面的经验。方法:进行回顾性研究,以确认威斯康星大学医院收治的所有患者。 1993年和2000年诊断出肠梗阻和转移癌。结果:共鉴定出114例主要为大肠或妇科恶性肿瘤的患者。患者的首次肠梗阻通过以下两种方式之一处理:(1)明确的外科手术干预(n = 47),或(2)保守治疗(n = 67)。整个研究组的平均总生存期为3 mo。根据处理,是否存在肠梗阻或原发癌类型,总体或无梗阻生存率无显着差异。唯一可预测总体生存不良的因素包括小于1年的无病间隔(诊断为原发癌的时间与肠梗阻的时间,p = 0.002)。结论:转移性癌症患者的肠梗阻为末期事件,中位生存期为3个月。因为根据管理,总体生存率或无阻塞生存率没有差异,所以应个体化转移癌患者的肠梗阻缓解治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号